Abstract: System and methods for risk and risk precursor identification in commercial aviation operations according to various aspects of the present invention operate in conjunction with a source of operation flight track data, a set of risk determination models containing instructions on how to process a set of received operational flight track data, a risk determination API for activating one or more risk models to process the set of received operational flight track data, and a user interface for communicating with the risk determination API. Each risk model may be trained to analyze flight track data to identify a particular type of risk precursor or identify a type of risk and any precursors that led to the risk. Processed results and identified risk precursors are forwarded to the user interface and displayed to allow users to quickly distinguish between nominal conditions for an aircraft and conditions with elevated levels of risk.

Abstract: An inventory control system for managing and transporting a subset of tools from a plurality of storage containers. Each of the plurality of storage containers can comprise a plurality of storage locations. Each storage location can store objects, wherein the objects can rest in a tray. Each storage location can comprise at least one image sensing device configured to capture image data of the plurality of storage locations. Each storage location can comprise a data processor configured to receive information representing captured images of the storage locations and data representing the usage or status of the objects associated with the images. The system can further comprise a portable container comprising a plurality of supplemental locations for storing the objects containers. The portable container can be configured to communicate with the plurality of storage locations and configured to reconcile objects shared between the portable container and the plurality of storage containers.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: An inventory control system comprises an object storage device, a display device, and one or more processors. The object storage device includes a plurality of compartments, in which each compartment has a plurality of storage locations for storing objects. The display device is configured to display information about the object storage device. The one or more processors are configured to establish a description database of objects configured for storage in the inventory control system. The one or more processors retrieve object keywords corresponding to objects stored in the plurality of storage locations of one of the plurality of compartments. The one or more processors also generate a text block based on the retrieved object keywords. On the display device, the one or more processors display a representation of the plurality of compartments of the object storage device with the text block applied to the one of the plurality of compartments.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: An inventory control system comprises an object storage device, one or more processors, a display device, and a mobile device. The object storage device includes a plurality of compartments, and each compartment includes a plurality of storage locations for storing objects. The one or more processors are configured to establish a database containing information regarding the object storage device, retrieve the information regarding the object storage device from the database, and generate an optical symbol based on the information regarding the object storage device. The display device is associated with the object storage device and configured to display the optical symbol. The mobile device is configured to capture an image of the optical symbol, obtain the information regarding the object storage device based on the image of the optical symbol, and display the information regarding the object storage device on a display screen of the mobile device.

Abstract: An inventory control system comprises an object storage device, a display device, and one or more processors. The object storage device includes a plurality of compartments, in which each compartment has a plurality of storage locations for storing objects. The display device is configured to display information about the object storage device. The one or more processors are configured to establish a description database of objects configured for storage in the inventory control system. The one or more processors retrieve object keywords corresponding to objects stored in the plurality of storage locations of one of the plurality of compartments. The one or more processors also generate a text block based on the retrieved object keywords. On the display device, the one or more processors display a representation of the plurality of compartments of the object storage device with the text block applied to the one of the plurality of compartments.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.

Abstract: Disclosed herein is a method for executing unprotected mode services in a protected mode computing environment includes initiating a protected mode service that is configured to execute in a protected mode. Further, the method includes verifying an integrity of one or more unprotected mode services configured to execute in an unprotected mode. The one or more unprotected mode services is registered with the protected mode service. The method also includes initiating an unprotected mode service of the one or more unprotected mode services in response to the integrity of the unprotected mode service being verified.

Abstract: Disclosed herein is a method for executing unprotected mode services in a protected mode computing environment includes initiating a protected mode service that is configured to execute in a protected mode. Further, the method includes verifying an integrity of one or more unprotected mode services configured to execute in an unprotected mode. The one or more unprotected mode services is registered with the protected mode service. The method also includes initiating an unprotected mode service of the one or more unprotected mode services in response to the integrity of the unprotected mode service being verified.

Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.

Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.